In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic’s Endeavor Stent Hits Primary Endpoint In Pivotal Trial

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's Endeavor zotarolimus-eluting stent is as effective as Boston Scientific's Taxus paclitaxel-eluting stent in the ENDEAVOR IV trial, Medtronic announced July 2

You may also be interested in...



Medtronic Bullish About Endeavor’s Chances In U.S. Market

Medtronic is confident being the late-comer to the U.S. drug-eluting stent market will not hinder its Endeavor zotarolimus-eluting coronary stent gaining market share

QUOTED. 6 April 2020. Bethany Hills.

Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.

UsernamePublicRestriction

Register

MT024997

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel